Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 818 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her... October 14, 2019 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Why People With Cancer Need to Be Taking Care of Their... August 27, 2020 The Galleri multi-cancer blood test: what you need to know September 13, 2021 Load more HOT NEWS Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with... How Does CAR T-Cell Therapy Work in Treating Cancer? Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... What to Know About Biomarker Testing for Lung Cancer: An Expert...
